5-bromo-3-pyridylacetone | 909849-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-3-pyridylacetone
• 英文别名: 1-(5-Bromopyridin-2-yl)propan-2-one
• CAS: 909849-33-8
• 化学式: C₈H₈BrNO
• 分子量: 214.062
• InChiKey: VMZYXUOZIGEKEP-UHFFFAOYSA-N

物化性质

• 沸点：
  263.3±25.0 °C(Predicted)
• 密度：
  1.473±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-3-pyridylacetone 、 乙酸酐 在 Eaton's reagent 作用下， 反应 1.0h， 生成 3-(5-Bromopyridin-2-yl)-2,6-dimethylpyran-4-one
  参考文献：
  名称：

  WO2006/94799

  摘要：

  公开号：
• 作为产物：
  描述：

  5-bromo-2-[2-nitro-1-propen-1-yl]pyridine 在 铁粉 、 溶剂黄146 作用下， 反应 2.0h， 生成 5-bromo-3-pyridylacetone
  参考文献：
  名称：

  WO2006/94799

  摘要：

  公开号：

文献信息

• Pyridinone Derivatives Against Malaria
  申请人：Fiandor Roman Jose Maria

  公开号：US20080287461A1

  公开（公告）日：2008-11-20

  4-pyridone derivatives of Formula (1) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

  本发明提供了式（1）的4-吡啶酮衍生物及其药学上可接受的衍生物，其制备过程，制药配方以及它们在治疗某些寄生虫感染（例如疟疾）的化疗中的应用。
• BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR
  申请人：Matsukawa Tatsuya

  公开号：US20110059957A1

  公开（公告）日：2011-03-10

  The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型苯并衍生物或噻吩衍生物，可用作VAP-1抑制剂，或用作预防或治疗VAP-1相关疾病等药物，即由公式（I）表示的化合物：其中每个符号如本说明书所定义，或其药学上可接受的盐。
• PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS
  申请人：QIAN Dapeng

  公开号：US20110212053A1

  公开（公告）日：2011-09-01

  Provided are compounds according to Formula (I): or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R 1 , R 6 , R 7 , and R 8 are as defined, and which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

  提供了以下式子(I)的化合物，或其立体异构体、前药、多晶形或药学上可接受的盐形式，其中X、Y、R1、R6、R7和R8如定义所述，这些化合物是有效的PI3-激酶和/或其他医学和临床相关的激酶抑制剂。还提供了制备这些化合物和组合物作为PI3-激酶和激酶抑制剂的制药组合物和使用方法。更具体地，本发明的化合物为通过PI3-激酶和/或蛋白激酶活性调节或相关联的人类疾病，或其突变或变异形式提供治疗和治疗方法。
• GDF-8 Inhibitors
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140107073A1

  公开（公告）日：2014-04-17

  Described are GCF-8 inhibitors of the formula (I), and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 5 , R 6 , X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.

  本文描述了式（I）的GCF-8抑制剂及其药学上可接受的盐，其中n、R1、R2、R5、R6、X和Z在此定义。还提供了包含这些化合物的制药组合物。这些化合物和组合物在抑制细胞中的GDF-8和治疗患有疾病或障碍的患者的方法中有用，其中患者从增加肌肉组织的质量或力量中获得治疗上的益处。
• 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170096409A1

  公开（公告）日：2017-04-06

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.